
 
 
 
 
 
 
 
 
   
 A  Bifidobacterium breve  CBT BR3 Bifidobacterium for promotion of growth, internationally deposited with the Korean Collection for Type Culture (KCTC) of the Korea Research Institute of Bioscience and Biotechnology under accession number KCTC 12201BP. 
 
     
 The Bifidobacterium of claim 1, having genes that degrade human milk oligosaccharides, wherein the genes include genes that encode α-mannosidase, β-mannosidase, endo-β- N -acetylglucosaminidase, sialidase, and α-fucosidase. 
 
     
 The Bifidobacterium of claim 1, comprising genes that biosynthesize nicotinic acid (B3) and folate (B9). 
 
     
 A nutraceutical composition, comprising a  Bifidobacterium breve  CBT BR3 strain (KCTC 12201BP) according to claim 1. 
 
     
 The nutraceutical composition of claim 4, comprising live or dried bacteria of the  Bifidobacterium breve  CBT BR3 strain (accession number: KCTC 12201BP) in an amount of 10 8  to 10 12  cfu/g. 
 
     
 The nutraceutical composition of claim 4, further comprising one or more other prebiotics selected from the group consisting of  Bifidobacterium longum  subsp.  infantis  CBT BT1 (KCTC 11859BP),  Bifidobacterium bifidum  CBT BF3 (KCTC 12199BP), and  Bifidobacterium longum  CBT BG7 (KCTC 12200BP). 
 
   
 
 
 
 
 
 
 
 
